Russia faced with decline of clinical trials of medicines

The number of clinical trials of drugs in Russia in 2022 significantly declined, according to latest data from the Russian Ministry of Health, reports The Pharma Letter’s local correspondent.

Last year the Ministry issued 18.5% fewer permits for such trials than in the year earlier. The decline was the result of the massive refusal of foreign companies to conduct their clinical trials within Russia, despite the fact that drugs and medical devices were not the subject of sanctions.

According to the Russian Kommersant business paper, citing data from the Russian Vademecum analytical center, in 2022 the Ministry of Health issued 740 permits to conduct clinical trials of drugs, of which 71% were accounted for Russian companies. The number of their trials increased by 21%. Foreign manufacturers have more than halved the number of their clinical trials in Russia.